Related Experiment Video
Updated: Feb 16, 2026

Cortisol Extraction from Sturgeon Fin and Jawbone Matrices
Published on: September 10, 2019
Hepatic phase I and II biotransformation responses and contaminant exposure in long-finned pilot whales from the
Katrin S Hoydal1, Bjørn M Jenssen2, Robert J Letcher3
1Department of Biology, Norwegian University of Science and Technology, Trondheim, Norway; Environment Agency, Traðagøta 38, FO-165, Argir, Faroe Islands.
Abstract:
Faroe Island pilot whales have been documented to have high body burdens of organohalogen contaminants (OHCs), including polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs), but low burdens of their respective hydroxylated metabolites (OH-PCBs and OH-PBDEs). The present study investigated the hepatic expression and/or catalytic activities of phase I and II biotransformation enzymes in relation to hepatic concentrations of target OHCs, including OH-PCBs and OH-PBDEs, in long-finned pilot whales (Globicephala melas) from the Northeastern Atlantic. CYP1A, 2B, 2E and 3A protein expressions were identified in juveniles and adult males, but not in adult females. Ethoxyresorufin-O-deethylase (EROD) activity was significantly lower in adult females than in juveniles and adult males. Using multivariate analyses to investigate relationships between biological responses and OHC concentrations, a positive relationship was identified between EROD and OHCs. The activity levels of phase II conjugating enzymes (uridine 5'-diphospho-glucuronosyltransferase [UDPGT], and glutathione S-transferase [GST]) were low. The analyses of mRNA expression did not show correlative relationships with OHC concentrations, but cyp1a and ahr transcripts were positively correlated with EROD activity. We suggest that the low concentrations of OH-PCBs and OH-PBDEs reported in pilot whales is probably due to the identified low phase I biotransformation activities in the species.
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Pilot and Numeric Relaying
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Contaminants and Errors
Another key consideration is determining the appropriate number of samples required to...

